Deciphera Pharmaceuticals

Home/Tag: Deciphera Pharmaceuticals

Blueprint & Deciphera Celebrate GIST Awareness Day 2020 – Galleries

Blueprint Medicines and Deciphera Pharmaceuticals celebrated GIST Awareness Day (GAD), July 13th, 2020, with Virtual Walks across the U.S. This year's GIST Awareness Day theme was #GISTHope.

By |2020-07-20T08:41:11-04:00July 17th, 2020|Advocacy, News, Photos|

Priority Review Granted for Ripretinib

Deciphera Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has accepted their New Drug Application (NDA) for ripretinib for Priority Review. Ripretinib is an investigational broad-spectrum KIT and PDGFRa inhibitor for the treatment of patients with gastrointestinal stromal tumors (GIST).

By |2020-02-14T09:57:21-05:00February 14th, 2020|Drug Treatment, News|

Deciphera Releases Positive Trial Results for Ripretinib

Deciphera Pharmaceuticals has released positive results from their INVICTUS Phase 3 Clinical Study of Ripretinib in patients with GIST. They have also updated results from the Phase 1 Study. Deciphera shared that "patients treated [...]

By |2019-08-14T09:38:14-04:00August 14th, 2019|Drug Treatment, News, Research|

Life Fest 2 Pharma Panel: Addressing Key Mechanisms of Tumor Drug Resistance

Pharma Panel: Overview of Promising Trials for GIST "Addressing Key Mechanisms of Tumor Drug Resistance" Deciphera Pharmaceuticals view all Life Fest 2018 Videos

By |2019-03-20T09:37:21-04:00September 18th, 2018|Clinical Trials, Events, Video|

Deciphera Pharmaceuticals Announces the Start of Phase 3 Clinical Trial with DCC-2618 in GIST

On January 4th, 2018 Deciphera Pharmaceuticals, Inc, announced the start of the Phase 3 INVICTUS trial. This randomized trial is for 4th line GIST patients that have failed (or are intolerant) the [...]

By |2018-10-29T13:46:27-04:00January 9th, 2018|Clinical Trials, News|
Go to Top